Antibe Therapeutics Inc (CVE:ATE)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.36 and traded as high as $0.39. Antibe Therapeutics shares last traded at $0.38, with a volume of 263,469 shares trading hands.
The company has a market capitalization of $102.69 million and a P/E ratio of -6.42. The stock’s 50 day moving average is C$0.36 and its 200-day moving average is C$0.33. The company has a debt-to-equity ratio of 45.01, a current ratio of 1.72 and a quick ratio of 1.04.
Antibe Therapeutics Company Profile (CVE:ATE)
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.
Read More: Backdoor Roth IRA
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.